Cargando…

Case Report: Case series: association between blood concentration and side effects of sotorasib

INTRODUCTION: Sotorasib is a crucial therapeutic agent for patients with non-small cell lung cancer (NSCLC) harboring the KRAS p.G12C mutation. Despite its efficacy, the relationship between blood sotorasib concentrations and side effects remains largely unexplored. METHODS: This study enrolled five...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shigaki, Ryota, Yoshida, Ryohei, Yagita, Akari, Nagasue, Kazunori, Naraoka, Taeka, Nitanai, Kiichi, Yanada, Hiraku, Tenma, Toshiyuki, Kida, Ryotaro, Umekage, Yasuhiro, Mori, Chie, Minami, Yoshinori, Sato, Hideki, Iwayama, Kuninori, Hashino, Yasuhisa, Fukudo, Masahide, Sasaki, Takaaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690615/ https://www.ncbi.nlm.nih.gov/pubmed/38044989 http://dx.doi.org/10.3389/fonc.2023.1269991

Ejemplares similares

Detection of resistance mutations in patients with anaplastic lymphoma kinase-rearranged lung cancer through liquid biopsy
por: Sasaki, Takaaki, et al.
Publicado: (2023)

Does the natural course of COVID‐19 infection include radiographic cystic changes?
por: Hirai, Noriko, et al.
Publicado: (2022)

Sotorasib: First Approval
por: Blair, Hannah A.
Publicado: (2021)

Correction to: Sotorasib: First Approval
por: Blair, Hannah A.
Publicado: (2021)

A Rare Event of Liver Dysfunction on Sotorasib and Management Strategy
por: Kinahan, Holly
Publicado: (2022)

Potential biomarkers uncovered by bioinformatics analysis in sotorasib resistant-pancreatic ductal adenocarcinoma
por: Ramalingam, Prasanna Srinivasan, et al.
Publicado: (2023)

Acute eosinophilic pneumonia following inhalation of turpentine oil: A case report
por: Umekage, Yasuhiro, et al.
Publicado: (2020)

Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib
por: Bauml, Joshua M., et al.
Publicado: (2022)

CodeBreak 200: Sotorasib Has Not Broken the KRAS(G12C) Enigma Code
por: Zhang, Shannon S, et al.
Publicado: (2023)

Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation?
por: Oya, Yuko, et al.
Publicado: (2023)

Integrative Analysis of Pharmacokinetic and Metabolomic Profiles for Predicting Metabolic Phenotype and Drug Exposure Caused by Sotorasib in Rats
por: Du, Ping, et al.
Publicado: (2022)

Spotlight on Sotorasib (AMG 510) for KRAS(G12C) Positive Non-Small Cell Lung Cancer
por: Zhang, Shannon S, et al.
Publicado: (2021)

Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
por: Lee, Arnold
Publicado: (2022)

DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS(G12C)-mutant cancer
por: Chiou, Li-Wen, et al.
Publicado: (2023)

Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib
por: Nolan, Aoife, et al.
Publicado: (2023)

Tolerability of sotorasib for KRAS positive lung adenocarcinoma patient with pre-existing interstitial pneumonia; A case report
por: Okada, Kohei, et al.
Publicado: (2023)

Correction to: Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
por: Lee, Arnold
Publicado: (2022)

Addressing Atropisomerism in the Development of Sotorasib, a Covalent Inhibitor of KRAS G12C: Structural, Analytical, and Synthetic Considerations
por: Lanman, Brian A., et al.
Publicado: (2022)

Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report
por: Begum, Parvin, et al.
Publicado: (2021)

Sotorasib Shows Intracranial Activity in Patients with KRAS G12C-Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases
por: Koster, Kira-Lee, et al.
Publicado: (2022)

CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
por: Brazel, Danielle, et al.
Publicado: (2023)

BCL-X(L) PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS(G12C)-mutated cancers
por: Khan, Sajid, et al.
Publicado: (2022)

Complete response to sotorasib as neoadjuvant treatment in patient with locally advanced primary pulmonary sarcoma harboring KRAS mutation: a case report
por: Li, Ce, et al.
Publicado: (2022)

Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report
por: Inno, Alessandro, et al.
Publicado: (2023)

Sotorasib in KRAS(G12C) mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
por: Olivier, Timothée, et al.
Publicado: (2022)

De Novo SCLC Transformation From KRAS G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report
por: Ito, Takanori, et al.
Publicado: (2023)

Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report
por: Iska, Sindu, et al.
Publicado: (2023)

Pulmonary vein thrombosis and cerebral infarction after video-assisted thoracic surgery of the left upper lobe: a case series
por: Fujii, Yosuke, et al.
Publicado: (2020)

Remarkable Intracranial Response to Sotorasib in a Patient With KRAS(G12C)-Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case Report
por: Yeh, Justin, et al.
Publicado: (2022)

Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)
por: Parums, Dinah V.
Publicado: (2022)

Incidence of Brain Metastases and Preliminary Evidence of Intracranial Activity With Sotorasib in Patients With KRAS(G12C)-Mutant Non–Small-Cell Lung Cancer
por: Lamberti, Giuseppe, et al.
Publicado: (2023)

Impact of symptoms by gender and age in Japanese subjects with irritable bowel syndrome with constipation (IBS-C): a large population-based internet survey
por: Kosako, Masanori, et al.
Publicado: (2018)

Influence of the requirement for abdominal pain in the diagnosis of irritable bowel syndrome with constipation (IBS-C) under the Rome IV criteria using data from a large Japanese population-based internet survey
por: Kosako, Masanori, et al.
Publicado: (2018)

Rapid Response to Sotorasib of a Patient With KRAS G12C-Mutated Lung Cancer With Cancer-Associated Disseminated Intravascular Coagulation: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2022)

Low concentrations of clarithromycin upregulate cellular antioxidant enzymes and phosphorylation of extracellular signal-regulated kinase in human small airway epithelial cells
por: Iwayama, Kuninori, et al.
Publicado: (2018)

Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea
por: Ida, Motoko, et al.
Publicado: (2017)

Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea
por: Ida, Motoko, et al.
Publicado: (2017)

Abdominal bloating is the most bothersome symptom in irritable bowel syndrome with constipation (IBS-C): a large population-based Internet survey in Japan
por: Kanazawa, Motoyori, et al.
Publicado: (2016)

Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

Long-term treatment of clarithromycin at a low concentration improves hydrogen peroxide-induced oxidant/antioxidant imbalance in human small airway epithelial cells by increasing Nrf2 mRNA expression
por: Iwayama, Kuninori, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ek4mognko0lg9c9s8j5na7hktu